[111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery

EJNMMI Research

Volumn 5, Issue 1, 2015, Pages 1-5

  Schottelius, Margret ^a   Wirtz, Martina ^a   Eiber, Matthias ^b   Maurer, Tobias ^b   Wester, Hans Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

111In; 177Lu; Imaging; PET; Prostate specific membrane antigen; PSMA; PSMA I T; Radioguided surgery; SPECT; Targeted radionuclide therapy

Indexed keywords

CD1 ANTIGEN; GALLIUM 68; INDIUM 111; LUTETIUM 177; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; AUTORADIOGRAPHY; CANCER STAGING; COMPETITIVE BINDING ASSAY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; IC50; LIPOPHILICITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NONHUMAN; PELVIS LYMPHADENECTOMY; PET-CT SCANNER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOSURGERY; RECURRENCE RISK; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

EID: 84948437469     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-015-0147-6     Document Type: Article

References (11)

1. Kiess A, Banerjee S, Mease R, Rowe S, Rao A, Foss C, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 2015;59:241–68.
2. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. Ga-68- and Lu-177-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76.
3. Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, et al. Ga-68-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333–41.
4. Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4(1):63.
5. Kulkarni H, Baum R, Weineisen M, Wester H, Schuchardt C, Wiessalla S, et al. Therapy of metastasized castrate-resistant prostate cancer using Lu-177 labeled DOTAGA-PSMA small molecules: first clinical results in a larger patient cohort. J Nucl Med. 2015;56(supplement 3):10.
6. Baum R, Kulkarni H, Volkmer B, Bohuslavizki K, Schuchardt C, Klette I, et al. Theranostics of metastatic prostate cancer applying 177Lu PSMA small molecules in combination with Ga-68 PSMA PET/CT. Nuklearmediziner. 2015;38:145–52.
7. Bernhard C, Moreau M, Lhenry D, Goze C, Boschetti F, Rousselin Y, et al. DOTAGA-anhydride: a valuable building block for the preparation of DOTA-like chelating agents. Chem Eur J. 2012;18:7834–41.
8. Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. Ga-68-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconj Chem. 2012;23:688–97.
9. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid (68)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74.
10. Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68:530–4.
11. Frisch B, Maurer T, Okur A, Weineisen M, Schottelius M, Kubler H, et al. Freehand SPECT for In-111-PSMA-I&T radioguided lymphadenectomy in prostate cancer patients. J Nucl Med. 2015;56(supplement 3):157.